Table 3 Responses to questionnaire on modified package leaflet (oral contraceptives with placebo comparison)
Extract of questionnaire | |||||
|---|---|---|---|---|---|
Frequency of side effects that were reported in a clinical trial on norgestimate/ ethinylestradiol (e.g. Amicette®) with 462 participants: | |||||
Norgestimate/ethinylestradiol | Placebo | ||||
Headache | 18.4 % | 20.5 % | |||
Painful or unusual periods | 10.1 % | 9.0 % | |||
Weight gain | 2.2 % | 2.1 % | |||
Question 1: If 100 women take this oral contraceptive – in how many women does the intake of this oral contraceptive cause (1) headache (2) painful or unusual periods (3) weight gain?a | |||||
Responses (No) | None | Lower frequency than listed in package leaflet | Same frequency as listed in package leaflet | Higher frequency than listed in package leaflet | No response |
Format free text | |||||
Group 2 (n = 27) Health science students | 0 | (1): 7 (26 %) | (1): 12 (44 %) | (1): 3 (11 %) | (1): 5 (19 %) |
0 | (2): 6 (22 %) | (2): 13 (48 %) | (2): 6 (22 %) | (2): 2 (7 %) | |
0 | (3): 7 (26 %) | (3): 13 (48 %) | (3): 2 (7 %) | (3): 5 (19 %) | |
Question 2: If 100 women do not take an oral contraceptive – in how many of them does (1) headache (2) painful or unusual periods (3) weight gain occur?b | |||||
Responses (No) | None | Lower frequency than listed in package leaflet | Same frequency as listed in package leaflet | Higher frequency than listed in package leaflet | No response |
Format free text | |||||
Group 2 (n = 27) Health science students | 0 | (1): 7 (26 %) | (1): 12 (44 %) | (1): 3 (11 %) | (1): 5 (19 %) |
0 | (2): 6 (22 %) | (2): 13 (48 %) | (2): 4 (15 %) | (2): 4 (15 %) | |
0 | (3): 6 (22 %) | (3): 13 (48 %) | (3): 3 (11 %) | (3): 5 (19 %) | |